Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant

Trial Profile

Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant

Not yet recruiting
Phase of Trial: Phase 0

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Autologous Epstein Barr virus specific T cell therapy Bluebird bio/University College London (Primary)
  • Indications Post-transplant lymphoproliferative disorder
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ITREC
  • Most Recent Events

    • 24 Oct 2017 Planned End Date changed from 15 Sep 2024 to 15 May 2025.
    • 24 Oct 2017 Planned primary completion date changed from 31 Oct 2019 to 30 Jun 2020.
    • 24 Oct 2017 Planned initiation date changed from 15 Sep 2017 to 15 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top